anti-androgens + metformin + lifestyle for PCOS
A systematic review and meta-analysis of RCTs found that adding anti-androgens to metformin + lifestyle lowered testosterone in PCOS, though hirsutism did not differ between combinations.
Hypothesized mechanism
Anti-androgens reduce circulating/active androgen levels (lower testosterone), potentially augmenting metformin and lifestyle effects in PCOS.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 7 of 10 overall, a moderate reading, from a direct rated moderate in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).
Corroboration
Evidence comes from a single systematic review and meta-analysis of randomised controlled trials, which counts as one synthesis source rather than independent replication. Per scoring rules, a single meta-analysis scores 1.
Rigor
The source is a systematic review and meta-analysis of randomised controlled trials, the highest rigor tier. This warrants a score of 2.
Specificity
Both the intervention (anti-androgens + metformin + lifestyle) and the condition (polycystic ovary syndrome) are named directly in the claims and source title.
Plausibility
The claims show an efficacy outcome (lower testosterone) consistent with anti-androgen action, but no explicit mechanism is detailed beyond the implied androgen-lowering effect. The mechanism is plausible but not evidenced in the provided claims.
Consistency
Findings are mixed: testosterone was lowered with the combination, but no difference in hirsutism was observed versus comparator arms. These point in differing directions for different outcomes, so the evidence is not clearly consistent; given limited claims, a neutral score is assigned.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Combination treatment with anti-androgens + metformin + lifestyle resulted in lower testosterone compared with metformin + lifestyle PubMed · PMID 37583655 ↗
- 2there were no differences in hirsutism when anti-androgens + metformin + lifestyle were compared with either anti-androgens + lifestyle or metformin + lifestyle PubMed · PMID 37583655 ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →